An­oth­er Shkre­li-like drug price con­tro­ver­sy? Lea­di­ant finds it­self in the spot­light af­ter 500-fold price hike — FT

Mar­tin Shkre­li may be cool­ing his heels in a fed­er­al prison, but the phar­ma pric­ing strat­e­gy he pur­sued that got him in­to an in­tense na­tion­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.